Evidence map›Paper›PMID 28785262›Full record

ArticleFrontiers in immunology2017

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.

Joana Vitallé, Olatz Zenarruzabeitia, Iñigo Terrén, Montserrat Plana, Alberto C Guardo, Lorna Leal, José Peña, Felipe García, Francisco Borrego

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Human IgMInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Joana VitalléImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Olatz ZenarruzabeitiaImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Iñigo TerrénImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Montserrat PlanaAIDS Research Group, IDIBAPS, HIVACAT, Hospital Clìnic, University of Barcelona, Barcelona, Spain.
Alberto C GuardoAIDS Research Group, IDIBAPS, HIVACAT, Hospital Clìnic, University of Barcelona, Barcelona, Spain.
Lorna LealAIDS Research Group, IDIBAPS, HIVACAT, Hospital Clìnic, University of Barcelona, Barcelona, Spain.
José PeñaInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Felipe GarcíaAIDS Research Group, IDIBAPS, HIVACAT, Hospital Clìnic, University of Barcelona, Barcelona, Spain.
Francisco BorregoImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
BioCruces Health research Institute · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat de Barcelona · ESBasque Center for Materials, Applications and Nanostructures · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A modified vaccinia Ankara-based HIV-1 vaccine clade B (MVA-B) has been tested for safety and immunogenicity in low-risk human immunodeficiency virus (HIV)-uninfected individuals and as a therapeutic vaccine in HIV-1-infected individuals on combined antiretroviral therapy (cART). As a therapeutic vaccine, MVA-B was safe and broadly immunogenic; however, patients still showed a viral rebound upon treatment interruption. Monocytes are an important part of the viral reservoir and several studies suggest that they are partly responsible for the chronic inflammation observed in cART-treated HIV-infected people. The CD300 family of receptors has an important role in several diseases, including viral infections. Monocytes express CD300a, c, e, and f molecules and lipopolysaccharide (LPS) and other stimuli regulate their expression. However, the expression and function of CD300 receptors on monocytes in HIV infection is still unknown. In this work, we investigated for the first time the expression of CD300 molecules and the cytokine production in response to LPS on monocytes from HIV-1-infected patients before and after vaccination with MVA-B. Our results showed that CD300 receptors expression on monocytes from HIV-1-infected patients correlates with markers of HIV infection progression and immune inflammation. Specifically, we observed a positive correlation between the expression of CD300e and CD300f receptors on monocytes with the number of CD4+ T cells of HIV-1-infected patients before vaccination. We also saw a positive correlation between the expression of the inhibitory receptor CD300f and the expression of CD163 on monocytes from HIV-1-infected individuals before and after vaccination. In addition, monocytes exhibited a higher cytokine production in response to LPS after vaccination, almost at the same levels of monocytes from healthy donors. Furthermore, we also described a correlation in the expression of CD300e and CD300f receptors with TNF-α production in response to LPS, only in monocytes of HIV-1-infected patients before vaccination. Altogether, our results describe the impact of HIV-1 and of the MVA-B vaccine in cytokine production and monocytes phenotype.

Indexed as

CD300CD300cCD300fHIV-1 vaccinehuman immunodeficiency viruslipopolysaccharidemonocytestherapeutic vaccine

Identifiers

PMID28785262
PMCPMC5520290
OpenAlexW2738102036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.